Federal managers can limit recommendations for the coche vaccine

Come this fall, only older Americans and those who have chronic health problems can be invited to get stuck – assuming the vaccine is available.

For years, the scientific advisers of the Centers for Disease Control and Prevention have debated the opportunity to continue to recommend to 6 -month -old Americans and to be immune, or to move to a so -called risk strategy that is only most vulnerable, as well as practice in most other countries.

Advisers should decide a way to follow at a meeting in June. But the debate may have become out of words. New requirements for clinical vaccine tests, announced earlier this month, can delay the availability of shots that had previously been updated each year without complicated trials.

“Substantial updates of existing vaccines – such as those linked to seasonal deformation changes or an antigen drift – can be considered” new products “and therefore require an additional clinical assessment,” the Ministry of Health and Social Services said in a press release.

This category includes the counted and “May” plans even include the seasonal flu vaccine, according to Andrew Nixon, spokesperson for HHS

Food and Drug Administration has already asked Novavax with more clinical data before approving its cocvid vaccine. (Currently, he has an emergency authorization, not a complete approval, for people aged 12 and over.)